Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450]

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
³ Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
⁴ Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
⁵ Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁶ Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
⁷ Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts. Electronic address: donald_kufe@dfci.harvard.edu.

Free article

Published Erratum

Naoki Haratake et al. J Thorac Oncol. 2025 Mar.

Free article

. 2025 Mar;20(3):399.

doi: 10.1016/j.jtho.2024.12.004. Epub 2024 Dec 18.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
³ Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
⁴ Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
⁵ Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁶ Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
⁷ Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts. Electronic address: donald_kufe@dfci.harvard.edu.

No abstract available

Erratum for

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D. Haratake N, et al. J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3. J Thorac Oncol. 2024. PMID: 37924972 Free PMC article.